L. Jones

Molecular Biology · with Liu · 2013–2021

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom L. Jones trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. B. Cravatt

Papers from L. Jones's perspective

Ordered by how strongly the researchers L. Jones trusts endorse each paper. Same corpus, a different order for every researcher.

  1. The Protein Kinase Complement of the Human Genome (Science)
  2. A small molecule–kinase interaction map for clinical kinase inhibitors (Nature Biotechnology)
  3. A quantitative analysis of kinase inhibitor selectivity (Nature Biotechnology)
  4. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. (Cancer Cell)
  5. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. (Cancer Research)
  6. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models (Oncogene)
  7. Halogen atoms in the modern medicinal chemistry: hints for the drug design. (Current Drug Targets)
  8. Screening for epidermal growth factor receptor mutations in lung cancer. (New England Journal of Medicine)
  9. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase (Nature)
  10. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. (Annual Review of Biochemistry)

Their papers